

ПРИОРИТИЗАЦИЯ ГЕНЕТИЧЕСКИХ ВАРИАНТОВ

Студенты: Исаев Василий, Лонишин Любовь

Руководители: Барбитов Юрий, Захаров Геннадий, Сидорук
Александр (Институт биоинформатики, ЕРАМ)






ГЛОБАЛЬНАЯ ЦЕЛЬ ПРОЕКТА

Разработать плагин-сортировщик мутаций по важности для NGB (New Genome Browser)

ЛОКАЛЬНЫЕ ЦЕЛИ

1. Написать **java**-утилиту для добавление в **VCF**-файл колонки с коэффициентом важности мутаций
2. Модифицировать написанную утилиту для уже обработанных **NGB**-браузером файлов
3. Встроить написанную утилиту в **NGB** - браузер

ЗАДАЧИ

1. Ознакомиться с программным кодом **NGB** и его интерфейсом 
2. Разработать функцию расчета потенциальной значимости
счета вариантов 
3. Протестировать разработанную функцию на реальных данных,
найти оптимальный метод расчета счета 
4. Разработать способ введения пользователем собственной
формулы для расчета счета 
5. Внедрение этой функции в **NGB** 

НАША ПРОГРАММА

1. VCF – файл парсится в отдельный класс для быстрого доступа к методам и полям.
2. Для каждой мутации перебираются заданные пользователем или дефолтные параметры для расчета коэффициента важности мутации.
3. Реализованы разнообразные способы параметров для расчета коэффициентов, с помощью которых можно задать любое выражение, от набора параметров, также реализованы параметры для дефолтного расчета коэффициента важности мутации

НАШ РЕПОЗИТОРИЙ



Search or jump to...



[Pull requests](#) [Issues](#) [Marketplace](#) [Explore](#)



[Vasily566](#) / [Mutations-Priority-Prediction-ToolVCFparser](#)

Unwatch ▾

2

★ Unstar

2

Fork

0

Code

Issues 1

Pull requests 0

Projects 0

Wiki

Insights

simple variant call format files parser

46 commits

1 branch

0 releases

2 contributors

Branch: **master** ▾

[New pull request](#)

[Create new file](#)

[Upload files](#)

[Find file](#)

[Clone or download ▾](#)



Vasily update

Latest commit 3c8d3bb 2 minutes ago

[bin](#)

test files updated

3 minutes ago

[src](#)

update

2 minutes ago

[.DS_Store](#)

remote trash

13 hours ago

[.classpath](#)

refactored structure

4 days ago

[.gitignore](#)

redone .gitignore

4 days ago

[.project](#)

rm trash

4 days ago

[TODO](#)

BEZOBRASIE

2 days ago

ТЕСТОВЫЕ ДАННЫЕ

Count

Likely benign

2.4%

Pathogenic

7.3%

Uncertain


22.0%

Likely pathogenic

9.8%

Benign

58.5%



USP9Y:c.6438+26dupT

Y-14954404 C>CT | dbSNP: [rs147207338](#)|[rs151160568](#) | [NM_004654.3](#) ⓘ

FOLLOW VARIANT

Suggested Classification

Benign





EVIDENCE

Aggregated from public databases using [ACMG Guidelines](#)

Population Data

ⓘ Contact us



Параметры, на которых основано наше предсказание:

- Данные о популяциях(+1.0 если <0.01)
 1. ExAC
 2. 1000 Genomes
 3. Exome Sequencing Project v.6500
- In silico предикторы(+0.5 – патогенная)
 1. PolyPhen2
 2. SIFT
 3. PROVEAN
- Базы данных о заболеваниях
 1. OMIM +1.0
 2. ClinVar (+1.5 патогенная, +1.0 возможно патогенная, -1.0 доброкачественная,
- Тип мутации (nonsense,

ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013

Sarah T. South, PhD^{1,2}, Charles Lee, PhD¹, Allen N. Lamb, PhD^{1,2}, Anne W. Higgins, PhD⁴ and Hutton M. Kearney, PhD⁵; for the Working Group for the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee

Disclaimer: These American College of Medical Genetics and Genomics *Standards and Guidelines* are developed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these standards and guidelines is voluntary and does not necessarily assure a successful medical outcome. These *Standards and Guidelines* should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her own professional judgment to the specific circumstances presented by the individual patient or specimen. Clinical laboratory geneticists are encouraged to document in the patient's record the rationale for the use of a particular procedure or test, whether or not it is in conformance with these *Standards and Guidelines*. They also are advised to take notice of the date any particular guideline was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.

Microarray methodologies, including array comparative genomic hybridization and single-nucleotide polymorphism-detecting arrays, are accepted as an appropriate first-tier test for the evaluation of imbalances associated with intellectual disability, autism, and multiple congenital anomalies. This technology also has applicability in prenatal specimens. To assist clinical laboratories in validation of

microarray methodologies for constitutional applications, the American College of Medical Genetics and Genomics has produced the following revised professional standards and guidelines.

Genet Med advance online publication 26 September 2013

Key Words: constitutional; guidelines; microarray; postnatal; prenatal; standards

GENERAL CONSIDERATIONS

Purpose of cytogenomic microarrays

Constitutional cytogenetic abnormalities include aneuploidy (extra or missing chromosomes) and structural aberrations (chromosomal gains and losses, translocations, inversions, insertions, and marker chromosomes). The cytogenomic microarray (CMA) platforms discussed in this guideline are those designed for the detection of DNA copy number gains and losses associated with unbalanced chromosomal aberrations. Regions with an absence of heterozygosity (AOH), also referred to as loss of heterozygosity, regions/runs of homozygosity, or long continuous stretches of homozygosity, may also be detected by platforms with single-nucleotide polymorphism (SNP)-detecting probes. Some regions with AOH may be indicative of uniparental isodisomy or regions of the genome identical by descent.

The utility of this technology for detection of gains and losses in patients with intellectual disabilities, autism, and/or congenital anomalies has been well documented, and CMA is now recommended as a first-tier test for these indications.^{1,2}

Advantages of CMAs

The benefits from the use of CMAs for detection of gains and losses of genomic DNA include:

1. Ability to analyze DNA from nearly any tissue, including archived tissue or tissue that cannot be cultured.
2. Detection of abnormalities that are cytogenetically cryptic by standard G-banded chromosome analysis.
3. Ability to customize the platform to concentrate probes in areas of interest.
4. Better definition and characterization of abnormalities detected by a standard chromosome study.
5. Interpretation of objective data, rather than a subjective visual assessment of band intensities.
6. Ability to detect copy neutral AOH with platforms incorporating SNP probes.
7. A ready interface of the data with genome browsers and databases.

¹ARUP Laboratories, Salt Lake City, Utah, USA; ²Department of Pathology, University of Utah, Salt Lake City, Utah, USA; ³Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; ⁴Department of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA; ⁵Pullerton Genetics Center, Mission Health, Asheville, North Carolina, USA. Correspondence: Sarah T. South (Sarah.South@aruplab.com)



Submitted 17 July 2013; accepted 17 July 2013; advance online publication 26 September 2013. doi:10.1038/jim.2013.129

ПОЛУЧЕННЫЕ ПОКАЗАТЕЛИ

1. Самые высокие показатели получены у патогенной и возможно патогенной мутаций
2. Аккуратность предсказания не очень высокая – 67,5%
3. Чувствительность – 100% (95% CI = 79.4% to 100.00)
4. **Вывод** – **данный бортировый Imy5 находит мутации, которые важны для клинициста**

ЧТО СДЕЛАНО?

1. Написана отдельная **java**-утилита, работающая с **VCF**-файлами, которая позволяет находить патогенные и возможно патогенные варианты
2. Найден оптимальный способ задания расчета коэффициента важности (а также возможен способ введения пользователем собственной формулы для расчета сора), который поднимает интересные для врача варианты наверх
3. В дальнейшем планируется встроить написанную утилиту в **NGB** – браузер



Тут должна будет появиться новая колонка

Type	Chr	Gene	Position	Info
INV	2	ALK, EML4	29224782	i
INV	2	ALK, EML4	29224783	i
INV	13	RB1	48367316	i
DUP	17	NF1	31200515	i
DUP	6		51294521	i
DEL	6		51294498	i
BND	6		51295112	i
BND	6		51295400	i
DEL	6	FILIP1	75314196	i
DEL	6	GRIK2	101802142	i
BND	6	ROS1	117314770	i
BND	6	RP1-179...	117320174	i
DEL	6	RP1-179...	117320381	i
DEL	6	RP1-179...	117321573	i
DEL	6	RP1-179...	117323215	i
DEL	6	RP1-179...	117324016	i
DEL	6	RP1-179...	117329434	i
DEL	6	RP1-179...	117331379	i

**[https://github.com/Vasiliy566/Mutations
-Priority-Prediction-ToolVCFparser](https://github.com/Vasiliy566/Mutations-Priority-Prediction-ToolVCFparser)**

СПАСИБО ЗА ВНИМАНИЕ!